Capricor Therapeutics CAPR
NASDAQ CAPR
$6.15 +0.27 (+4.59%)
As of: Oct 22, 2026 · 2:16 PM EDT

Capricor Therapeutics (CAPR) Short term Debt (2017)

Updated

Capricor Therapeutics (CAPR) reported Short term Debt of $14.16 million for Q3 2017, unchanged from the prior quarter.

Analysis

Capricor Therapeutics (CAPR) Short term Debt (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,169.76 Bn 1,138.35 Bn 19.71 Bn
2 Johnson & Johnson 648.06 Bn 567.92 Bn 17.30 Bn
3 AbbVie 503.37 Bn 476.48 Bn 12.70 Bn
4 Merck 365.39 Bn 319.77 Bn 12.21 Bn
5 Novartis Ag 303.45 Bn 267.44 Bn 11.24 Bn
6 Astrazeneca 269.03 Bn 242.72 Bn 12.86 Bn
7 Amgen 242.08 Bn 197.48 Bn 7.24 Bn
8 Gilead Sciences 194.88 Bn 169.07 Bn 6.22 Bn
9 Pfizer 172.39 Bn 119.04 Bn 10.94 Bn
10 Capricor Therapeutics 353.06 Mn -580.18 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2017 14.16 Mn
Jun 30, 2017 14.16 Mn
API Access

Capricor Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=CAPR&period=max&api_key=YOUR_API_KEY